Headshot photo of Brian J. Druker, M.D.

Brian J. Druker, M.D.

  • Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
  • Associate Dean, Oncology, Office of the Dean, School of Medicine
  • CEO, OHSU Knight Cancer Institute, School of Medicine
  • JELD-WEN Chair of Leukemia Research
  • Cancer Biology Graduate Program, School of Medicine
  • Program in Molecular and Cellular Biosciences, School of Medicine


Brian Druker, M.D., revolutionized the treatment of cancer through research that resulted in the first drug to target the molecular defect of a cancer while leaving healthy cells unharmed. Marketed under the name Gleevec®, his discovery turned a once-fatal cancer, chronic myeloid leukemia, into a manageable condition.

Treatment with Gleevec received FDA approval in record time, was featured on the cover of Time magazine, and established Druker as a pioneer in the field of precision medicine.  Most important, his discovery became a new proof of principal for targeted therapies, spurring the development of more than 50 similar precision therapies for other cancers.

Druker now is applying key principles of precision medicine to early detection. Earlier detection of lethal cancers represents the greatest opportunity to increase cancer survival rates. Thanks to $1 billion in philanthropic funding, Druker is developing a large-scale early detection program that builds upon the scientific strengths of OHSU’s Knight Cancer Institute.

Druker has been recognized with numerous awards, including the Sjöberg Prize from the Royal Swedish Academy of Sciences, the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology, the Tang Prize in Biopharmaceutical Science, and the Prince Mahidol Award for outstanding achievements in medicine and public health worldwide. He has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences.

Education and training

  • Degrees

    • M.D., 1981, University of California San Diego
  • Residency

    • Barnes Hospital, Washington University, St. Louis
  • Fellowship

    • Medical oncology - Dana-Farber Cancer Institute, Harvard Medical School, Boston
  • Certifications

    • American Board of Internal Medicine, 1984

Memberships and associations:

  • Institute of Medicine: National Academy of Sciences
  • American Association of Physicians
  • National Academy of Sciences
  • American Society for Clinical Investigation
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American Society for Microbiology
  • Children’s Oncology Group
  • The American Society for Cell Biology


Elsevier pure profile


  • {{ pub.journalAssociation.journal.name.text[0].value }}